ViiV Healthcare, announced on 5/21/18 that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human... read more
ViiV Healthcare, announced on 5/21/18 that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human... read more
PROCEPT BioRobotics, a Silicon Valley robotics company developing intelligent surgical solutions to transform the field of urology, has announced early data from the global Phase III WATER II (... read more
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced on 5/18/18 a poster presentation of additional prostate cancer data (Abstract #229675) at the American Society of Clinical Oncology (ASCO)... read more
Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, today announced $40 million in Series A capital to establish a discovery platform and... read more
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... read more